Cannell & Spears’s Idexx Laboratories IDXX Stock Holding History

Cannell & Spears’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.78M	Buy	7,177 +1	+0%	+$561	0.07%	163
2026 Q1	$4.03M	Sell	7,176 -1,900	-21%	-$1.22M	0.08%	147
2025 Q4	$6.14M	Hold	9,076	–	–	0.11%	122
2025 Q3	$5.8M	Buy	9,076 +5	+0.1%	+$3.04K	0.11%	131
2025 Q2	$4.87M	Sell	9,071 -1	-0%	-$478	0.1%	140
2025 Q1	$3.81M	Buy	9,072 +7,901	+675%	+$3.43M	0.08%	154
2024 Q4	$484K	Sell	1,171 -399	-25%	-$175K	0.01%	288
2024 Q3	$793K	Buy	1,570 +400	+34%	+$194K	0.02%	258
2024 Q2	$570K	Sell	1,170 -400	-25%	-$201K	0.01%	260
2024 Q1	$848K	Buy	1,570 +400	+34%	+$219K	0.02%	238
2023 Q4	$649K	Hold	1,170	–	–	0.05%	122
2023 Q3	$512K	Hold	1,170	–	–	0.04%	131
2023 Q2	$588K	Buy	1,170 +400	+52%	+$192K	0.05%	126
2023 Q1	$385K	Hold	770	–	–	0.03%	159
2022 Q4	$314K	Buy	+770	New	+$299K	0.03%	175

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Cannell & Spears's IDXX Position: Q2 2026 in Review

Cannell & Spears increased its Idexx Laboratories (IDXX) stake by 0.01% in Q2 2026, buying an estimated $561 and bringing the position to 7,177 shares worth $3.78M. The position accounts for 0.07% of the portfolio, ranked #163.

Cannell & Spears first reported a position in IDXX in Q4 2022 and has held it in 15 quarters since. The position peaked at $6.14M in Q4 2025. 1,301 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Cannell & Spears held 7,177 shares of Idexx Laboratories worth $3.78M as of Q2 2026.
Cannell & Spears bought 1 Idexx Laboratories share in Q2 2026, an estimated $561.
Idexx Laboratories made up 0.07% of Cannell & Spears's portfolio in Q2 2026, its #163 holding.
Cannell & Spears first reported a position in Idexx Laboratories in Q4 2022 and has held it in 15 quarters since.
Cannell & Spears's Idexx Laboratories position peaked at $6.14M in Q4 2025.
1,301 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Cannell & Spears's 13F filing for Q2 2026, filed 11 Aug 2026.